Literature DB >> 11351219

[ICG angiography and retinal pigment epithelial decompensation (CRSC and epitheliopathy)].

F Bandello1, G Virgili, P Lanzetta, A Pirracchio, U Menchini.   

Abstract

PURPOSE: To evaluate the prognosis of chronic central serous chorioretinopathy (CSC) and to assess whether certain clinical and angiographic features are associated with increased risk of vision loss.
METHODS: All of the 51 patients with chronic CSC, who had received a baseline evaluation with fluorescein angiography (FA) and indocyanine green angiography (ICGA), during the last 5 years were retrospectively included in the study.
RESULTS: The mean age was 49 years (range: 28-77 years). Sixteen out of 102 eyes (15.7%) of 14 patients lost at least 3 lines (0.3logMAR) after a mean follow-up of 34.7 months (range: 12-72 months). Logistic regression showed that CSC onset more than 7 years before inclusion (odds ratio: 4.3, p=0.024) and having areas of confluent RPE atrophy with FA at baseline (at least 2 disc diameters, odds ratio: 4.9,p=0.020) were independently associated with vision loss. Choroidal neovascularization was observed during follow-up in 4 eyes of 3 patients.
CONCLUSION: Disease duration of more than 7 years and the presence of confluent RPE atrophy independently characterized CSC patients at higher risk for visual loss in our series.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11351219

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  9 in total

1.  [Central serous chorioretinopathy (CSC)].

Authors:  H Baraki; N Feltgen; J Roider; H Hoerauf; C Klatt
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

2.  Retinal pigment epithelium apertures as a late complication of longstanding serous pigment epithelium detachments in chronic central serous chorioretinopathy.

Authors:  Claudio Iovino; Jay Chhablani; Deepika C Parameswarappa; Marco Pellegrini; Giuseppe Giannaccare; Enrico Peiretti
Journal:  Eye (Lond)       Date:  2019-07-02       Impact factor: 3.775

3.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

4.  Prognostic factors related to photodynamic therapy for central serous chorioretinopathy.

Authors:  Jun Woong Moon; Hyeong Gon Yu; Tae Wan Kim; Hyung Chan Kim; Hum Chung
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-07       Impact factor: 3.117

Review 5.  Verteporfin PDT for non-standard indications--a review of current literature.

Authors:  Wai Man Chan; Tock-Han Lim; Alfredo Pece; Rufino Silva; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

Review 6.  Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options.

Authors:  Francesco Sartini; Michele Figus; Marco Nardi; Giamberto Casini; Chiara Posarelli
Journal:  Eye (Lond)       Date:  2019-03-01       Impact factor: 3.775

7.  Indocyanine green angiography in chronic central serous chorioretinopathy.

Authors:  Urszula Gajdzik-Gajdecka; Mariola Dorecka; Ewa Nita; Anna Michalska; Joanna Miniewicz-Kurowska; Wanda Romaniuk
Journal:  Med Sci Monit       Date:  2012-02

8.  Central serous chorioretinopathy mistaken for tuberculous choroiditis.

Authors:  Marina Papadia; Carl P Herbort
Journal:  J Ophthalmic Vis Res       Date:  2011-10

9.  Correlation between Choroidal Neovascularization Shown by OCT Angiography and Choroidal Thickness in Patients with Chronic Central Serous Chorioretinopathy.

Authors:  Joanna Gołębiewska; Joanna Brydak-Godowska; Joanna Moneta-Wielgoś; Monika Turczyńska; Dariusz Kęcik; Wojciech Hautz
Journal:  J Ophthalmol       Date:  2017-10-04       Impact factor: 1.909

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.